Form D · Biotechnology
Hexagon Bio Inc.
Menlo Park, CA · CIK 0001712416
Offering snapshot reported Oct 11, 2022 · SEC filing
- Reported sold
- $67.3M Offering amount: $80M
- Investors reported
- 20 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 30, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 11, 2022 | Initial | $67,319,323 | No comparison | 20 | SEC filing |
| Jul 19, 2021 | Initial | $61,000,001 | No comparison | Not reported | SEC filing |
| Jul 31, 2018 | Initial | $12,000,000 | No comparison | 12 | SEC filing |
| Jul 20, 2017 | Initial | $8,299,990 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-461285
Source: Form D, filed Oct 11, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Goeddel | Director |
| Colin James Bell Harvey | Director, Executive |
| Maureen E Hillenmeyer | Director, Executive |
| Juan Jaen | Director |
| Alex Kolich | Director |
| Alex Kolicich | Director |
| Jakob Loven | Director |
| Brian T Naughton | Director, Executive |
| Mridula Ray | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1490 O'brien Drive Suite E
Menlo Park, CA, 94025
Menlo Park, CA, 94025